Boston Scientific (BSX) Net Cash Flow (2009 - 2026)

Boston Scientific has disclosed Net Cash Flow across 18 years of filings, most recently posting -$892.0 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 395.56% year-over-year to -$892.0 million; the TTM figure through Jun 2026 stood at $10.0 million (up 100.42% YoY), while the FY2025 annual figure was $1.5 billion, up 442.24% from the prior year.
• Net Cash Flow came in at -$892.0 million for Q2 2026 at Boston Scientific, down from -$503.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.4 billion in Q1 2024 to a low of -$2.0 billion in Q4 2024.
• Average Net Cash Flow over 5 years is -$79.6 million, with a median of -$73.5 million recorded in 2022.
• Year-over-year, Net Cash Flow jumped 6844.44% in 2022 and sank 2411.11% in 2024.
• Over 5 years, Net Cash Flow stood at $625.0 million in 2022, then slumped by 112.96% to -$81.0 million in 2023, then slumped by 2411.11% to -$2.0 billion in 2024, then surged by 132.84% to $668.0 million in 2025, then slumped by 233.53% to -$892.0 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$892.0 million in Q2 2026, -$503.0 million in Q1 2026, and $668.0 million in Q4 2025.